Navigation Links
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol(TM) has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.

"The decision by the FDA to grant Rhitol(TM) orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.

About Rhitol(TM)

Rhitol(TM) is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol(TM) treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.

About chronic GvHD

GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient's tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as ster
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clinverse, Inc. , a ... trials, announced today it has formed a strategic ... ClinPay® FLS eClinical commerce platform aggregates data collected ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship product, ... reporting transfer of value at investigator meetings or ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... Bed bugs have become so widespread in the past ... to chemical-based pesticides for help to completely get rid of ... solutions present, the company advised the public to kill ... According to My Cleaning Products, chemical-based pesticides are not as ... shared that the pests have already developed immunity to the ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer ... today,announced that it plans to release third quarter 2007 ... close. The company will hold a conference call ... its fiscal third quarter results. Listeners may access the,call ...
... Calif., Oct. 25 ,Exelixis, Inc. (Nasdaq: EXEL ) ... November 5, 2007, after the markets close. The,announcement will ... PST/5:00 p.m.,EST, in which Exelixis management will discuss the ... may be accessed in the,Event Calendar page under Investors ...
... Blocks of carbon nanotubes can be used to create ... study by researchers at Rensselaer Polytechnic Institute. , Taking ... researchers repeatedly squeezed a 3-millimeter nanotube block and discovered ... pressure sensor. No matter how many times or how ...
Cached Biology Technology:American Oriental Bioengineering Announces Reporting Date for Third Quarter 2007 Financial Results 2The sensitive side of carbon nanotubes: Creating powerful pressure sensors 2The sensitive side of carbon nanotubes: Creating powerful pressure sensors 3
(Date:5/22/2013)... (May 22, 2013)The omega 3 fatty acids in fish ... diseaseso much so that the American Heart Association currently ... week, particularly fatty varieties rich in omega 3s. However, ... mystery. In a new study, scientists led by Jason ... this phenomenon by providing evidence that fish oil might ...
(Date:5/22/2013)... Adventitious changes in cellular DNA can endanger the whole ... cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report ... the double helix. , The DNA in our cells ... in our bodies. The instructions for this are encoded ... in DNA, the bases adenine (A), cytosine (C), guanine ...
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
Breaking Biology News(10 mins):Fish oil may help the heart beat mental stress 2DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... largest field trial of its kind in the United ... Miscanthus x giganteus outperforms current biofuels sources by ... production in the U.S. could significantly reduce the acreage ... the researchers report. The new findings, from researchers ...
... nutritious plant. The research paper, published with colleagues ... appeared in the early online edition of the Proceedings ... of July 21. "There,s a lot of attention today ... investigator on the study and one of the authors of ...
... Immunopathogenesis Consortium (CLIC), a group of researchers from 10 ... Canada led by physicians at Case Western Reserve University ... million dollar grant from the National Institutes of Health ... progressive immune deficiency that causes AIDS. The grant will ...
Cached Biology News:Miscanthus can meet US biofuels goal using less land than corn or switchgrass 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 3Dartmouth researchers identify an important gene for a healthy, nutritious plant 2Case Western Reserve University School of Medicine researchers receive $10.8 million 2
... a macromolecular structure has been determined, the ... a widely diverse audience of scientists, educators ... literature and dissemination over the Internet, either ... web pages. Printed literature has the advantage ...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
... 2 Block MBS Start up kit. Includes ... and choice of 2 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
Biology Products: